Research programme: FPR2 agonists - Bristol-Myers Squibb/kyorin pharmaceutical

Drug Profile

Research programme: FPR2 agonists - Bristol-Myers Squibb/kyorin pharmaceutical

Latest Information Update: 18 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kyorin Pharmaceutical
  • Developer Bristol-Myers Squibb; Kyorin Pharmaceutical
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action FPR2 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammation

Most Recent Events

  • 03 Feb 2016 Preclinical trials in Inflammation in Japan (unspecified route) (Kyorin pharmaceuticals' pipeline, February 2016)
  • 09 Dec 2015 Kyorin Pharmaceutical and Bristol-Myers Squibb enter into licensing agreement for FPR2 worldwide for undisclosed indications
  • 09 Dec 2015 Early research in Inflammation in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top